Is UroGen Pharma Ltd. overvalued?

UroGen Pharma Ltd. (URGN) — key valuation metrics and fundamentals.

No verdict

Price

$40.94

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$1.99B

Dividend yield

0.0%

Return on equity

81.8%

Sector

Healthcare

Fair value compares URGN's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.

Related stocks